Every 10 seconds 1 individual in the UK has an asthma attack, with studies showing that 67% of asthma-related deaths are preventable through better asthma care. Along with this, it was noted that 70-90% of the time inhalers are used incorrectly, further amplifying the issue. With correct inhaler usage, 50% of medicine reaches the lungs. Over time, complacency when using a breathing actuator results in a risk to the patient’s health, with patients seeing as little as 7% efficiency when used incorrectly. Flohaler, a PMDI (Pressurised Meter Dose Inhaler), has been designed to promote optimum posture by encouraging patients to lift their chin, straightening their throat to ensure maximum medicine inhalation into the lungs. This is achieved through Flohaler’s unique design, which prompts the user to grip rather than pinch the inhaler. Coupled with an angled mouthpiece, this makes it harder and more uncomfortable for the patient to use incorrectly. Through doing this, enhanced airflow is achieved when using the device, maximising the amount of medicine reaching the lungs. A clear expiry date and remaining dose counter helps patients to easily identify when the inhaler needs replacing, encouraging action. Research suggests that 35% of inhalers expire sooner than expected, with 26% of patients not knowing when it expires at all. Incorporating braille into the design, alongside a considered colour palette that enhances inhaler recognition for those with colour vision deficiency (Deuteranopia, Protanopia and Tritanopia) further enhances Flohaler’s functionality for visually impaired users, which effects 8% of the UK population. Flohaler’s simplistic design maintains manufacturing price competitiveness (compared to other similar PMDI inhalers), utilising current manufacturing assembly processes whilst offering a higher perceived value. This enhances the commercial viability to help reduce the number of preventable asthma-related deaths and emergency admissions.